Non-small cell lung cancer (NSCLC) has made a remarkable development in recent decades with respect to its perception. In the late 1990s it was the "problem child" as the main cause of cancer with increasing tendencies, especially in women and with a pronounced stigmatization. It is now the role model as a biologically rational targeted treatment based on molecular dependencies of the tumor with a vast improvement of the traditionally poor survival times. Molecular tumor boards have long followed the NSCLC example in the assessment of targeted treatment approaches for other tumor entities. This review article gives an overview of the current possibilities for targeted treatment of NSCLC, which nowadays are applicable for nearly one third of all patients with NSCLC.
机构:
Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 600 16th St,N212D, San Francisco, CA 94158 USAUniv Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA
Halliday, Patrick R.
Blakely, Collin M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 600 16th St,N212D, San Francisco, CA 94158 USAUniv Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA
Blakely, Collin M.
Bivona, Trever G.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 600 16th St,N212D, San Francisco, CA 94158 USAUniv Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA